Pacific Biosciences
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1305 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 521-8000Website
www.pacb.comRevenue
$160 MillionStock Symbol
PACBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
1
1
1
1
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.Explore more
Pacific Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pacific Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pacific Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Pacific Biosciences launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pacific Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pacific Biosciences
Check out if Pacific Biosciences is spiking on competitors!
Check if Pacific Biosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pacific Biosciences has new funding data
Click to see if Pacific Biosciences had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Pacific Biosciences
Find 3 more new buyers
Compare Similar Companies to Pacific Biosciences
Compare insights from companies similar to Pacific Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Pacific Biosciences
$160M
201-500
Public
$1.6B
2004
Christian HenryPresident, CEO & Interim Chief Financial Officer
Company Profile Activity
Activity Insights
Pacific Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pacific Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pacific Biosciences.
Pacific Biosciences financials insights
Gather financial insights about Pacific Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series D
$50M
2008
Series E
$100M
2009
Other Financing Round
$68M
2010
Series F
$109M
Stock Offering
$200M
2013
Debt
$20.5M
2018
Stock Offering
$30M
Stock Offering
$60M
2021
Series A
$900M
Pacific Biosciences Tech Stack
A closer look at the technologies used by Pacific Biosciences
See more technologies
Most Recent Scoops
Project
Pacific Biosciences has announced plans to launch Spark Next chemistry for its Vega instrument in H2 2025, a new chemistry designed to enable lower sample volumes and higher data output, including 30x whole genome sequencing capability on the Vega platform.
Pain Point
experienced delivery delays due to Middle East conflict headwinds, resulting in approximately $1 million of revenue held on ships, though the company has since confirmed that the delayed revenue has been delivered.
Logistics / Supply Chain, Finance, Risk
Earnings
Pacific Biosciences has reduced its full-year revenue guidance by $5 million, reflecting the assumption that academic and government customers will remain slow for both its Revio and Vega instruments for the remainder of the year, following weaker-than-expected demand from that segment in Q1.
Earnings
Pacific Biosciences has reported a gross margin of 37% for Q1, with full-year gross margin guidance set at 41% to 44%, as Q1 results were impacted by the Flying Solo promotion (approximately 150 basis points), pre-purchased DRAM at elevated prices, and one-time warranty charges not expected to recur.
Earnings, Finance
Open Position
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pacific Biosciences
Sign Up For FreeTo access detailed company insights
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectr... Read More
